2021
1102P The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses
Ruszniewski P, Caplin M, Kunz P, Bodei L, Hendifar A, Mittra E, Wolin E, Yao J, Pavel M, Grande E, Van Cutsem E, Seregni E, Duarte H, Demange A, Mutevelic S, Krenning E, Strosberg J. 1102P The phase III NETTER-1 study of 177Lu-DOTATATE in patients with midgut neuroendocrine tumours: Further survival analyses. Annals Of Oncology 2021, 32: s911-s912. DOI: 10.1016/j.annonc.2021.08.184.Peer-Reviewed Original ResearchFinal overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.
Strosberg J, Caplin M, Kunz P, Ruszniewski P, Bodei L, Hendifar A, Mittra E, Wolin E, Yao J, Pavel M, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Demange A, Mutevelic S, Krenning E, group O. Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. Journal Of Clinical Oncology 2021, 39: 4112-4112. DOI: 10.1200/jco.2021.39.15_suppl.4112.Peer-Reviewed Original ResearchProgression-free survivalMedian overall survivalFinal overall survivalNETTER-1 studyNETTER-1 trialNew safety signalsOverall survivalMidgut neuroendocrine tumorsControl armMyelodysplastic syndromeNeuroendocrine tumorsLu-DOTATATEPrimary endpointLast patientSafety signalsFurther anti-cancer treatmentBest supportive careKey secondary endpointOpen-label trialLutetium-177 DOTATATEAnti-cancer treatmentEligible patientsNETTER-1RECIST 1.1Secondary endpoints
2020
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study
Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taïeb D, Mittra E, Wolin E, O’Dorisio T, Lebtahi R, Deroose CM, Grana CM, Bodei L, Öberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 47: 2372-2382. PMID: 32123969, PMCID: PMC7396396, DOI: 10.1007/s00259-020-04709-x.Peer-Reviewed Original ResearchConceptsLiver tumor burdenProgression-free survivalLargest target lesionHigher liver tumour burdenTumor burdenMidgut neuroendocrine tumorsAlkaline phosphatase elevationNeuroendocrine tumorsTarget lesionsLesion sizeHazard ratioTreatment outcomesAnalysis of PFSHigh-dose octreotide LARMedian progression-free survivalImproved progression-free survivalNETTER-1 studyNETTER-1 trialLiver function abnormalitiesKaplan-Meier estimatesOctreotide LARPrimary endpointFunction abnormalitiesBaseline factorsCox regressionSingle institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET).
Duan H, Ninatti G, Girod B, Ferri V, Kunz P, Fisher G, Moradi F, Davidzon G, Franc B, Iagaru A, Mari C. Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET). Journal Of Clinical Oncology 2020, 38: 623-623. DOI: 10.1200/jco.2020.38.4_suppl.623.Peer-Reviewed Original ResearchPeptide receptor radionuclide therapyNETTER-1 trialObjective response rateProgression-free survivalNETTER-1 studyReceptor radionuclide therapyNeuroendocrine tumorsCycles of PRRTRadionuclide therapyInterim overall survival analysisProgressive neuroendocrine tumorsLines of therapySingle institution experienceOnly side effectMidgut neuroendocrine tumorsTreatment of patientsCourse of treatmentOverall survival analysisPFS ratesMetastatic diseaseCurative treatmentInstitution experiencePatient cohortSide effectsVs. 18
2018
1316P Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study
Strosberg J, Hendifar A, Yao J, Kulke M, O’Dorisio T, Caplin M, Baum R, Kunz P, Hobday T, Wolin E, Mittra E, Oberg K, Ruszniewski P, Polack B, He B, Barton D, Santaro P, Krenning E. 1316P Impact of liver tumor burden on therapeutic effect of 177Lu-dotatate treatment in NETTER-1 study. Annals Of Oncology 2018, 29: viii471. DOI: 10.1093/annonc/mdy293.009.Peer-Reviewed Original Research